Translational Advances in the Field of Pulmonary Hypertension.Translating MicroRNA Biology in Pulmonary Hypertension. It Will Take More Than “miR” Words

Magnetic Resonance Imaging in the Prognostic Evaluation of Patients with Pulmonary Arterial Hypertension

“…Although this is a retrospective study, it is consistent with a prospective double-blinded study, which showed the benefit of sequential combination therapy over monotherapy in patients with PAH (43) in reducing clinical worsening and a MRI focused study of up front combination therapy in systemic sclerosis which demonstrated improvements in RV function (44). Despite improved outcomes PAH remains a life shortening condition and identification of reproducible and prognostic end-points in PAH will help to assess the value of new therapeutic agents (45).…”

Implication of Inflammation and Epigenetic Readers in Coronary Artery Remodeling in Patients With Pulmonary Arterial Hypertension

“…We and others have described the implication of the receptor of advanced glycation endproducts, 2-4 the oncoprotein kinase Pim-1 3,5 and the transcription factor nuclear factor of activated T cells 6,7 in promoting proliferation in remodeling processes occurring in both VRD and PAH. In PAH patients' lung vasculature, these molecular actors are, at least in part, regulated by proinflammatory cytokines, alterations in the miR-223/DNA damage/ Poly[ADP-ribose] polymerase 1/miR-204 axis [8][9][10][11] and subsequent overexpression of the epigenetic reader bromodomain protein 4 (BRD4). 12 BRD4 functions as a scaffold for transcription factors at promoters and superenhancers, modulating the chromatin landscape and facilitating transcriptional activation of target genes.…”

Discerning functional hierarchies of microRNAs in pulmonary hypertension

“…Mirroring the emerging trends of RNA-based diagnostics, the prospects of miR-NA-specific therapies to augment or knockdown miRNAs are at their inception. Although some miRNAs have been proposed as potential therapeutic targets in PH (19), their clinical potential remains an open question. Primarily, miRNA-based therapeutic strategies have concentrated on the development of stabilized oligonucleotide mimics or inhibitors, but these have yet to be explored in clinical trials for PH.…”